Rezaul Karim, PhD, possesses a rich and diverse background in regulatory affairs and pharmaceutical development, with considerable relevance to radiopharmaceuticals.

In his current position as a Regulatory Affairs Manager at Starodub BV, a regulatory consulting company based in the Netherlands, he provides consulting services on various aspects of (bio)pharmaceutical development, including CMC (Chemistry, Manufacturing, and Controls) and non-clinical development of various products, including radiopharmaceuticals.

Rezaul's prior experience in evaluating biologicals at a WHO-Utrecht University center and working in a NASDAQ-listed biotech company in the Netherlands focusing on cancer immunotherapies further underscores his understanding of complex biological systems, which is relevant in the development of radiopharmaceuticals targeting cancer cells or specific molecular pathways.

His PhD in cancer immunology including a postdoctoral fellowship in cancer biology provide him with a strong scientific foundation that can be applied to the development and evaluation of radiopharmaceuticals designed for cancer diagnosis and treatment.

In summary, Rezaul Karim's experience and expertise exhibit significant relevance to (bio/radio)pharmaceuticals, particularly in areas such as regulatory affairs, CMC, non-clinical/toxicology, and biological safety evaluation, making him well-equipped to contribute to the development and support in regulatory approval of (bio/radio)pharmaceuticals.